Skip to content
Saturday, October 17, 2026
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
IceCure and Scovas agree for ProSense distribution in Netherlands
McKesson to buy Precision Medicine Group for $2.25bn

Insure Health

Newsletter
Random News
  • About US
  • Contact US
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
IceCure and Scovas agree for ProSense distribution in Netherlands
McKesson to buy Precision Medicine Group for $2.25bn

Insure Health

Newsletter
Random News
  • About US
  • Contact US
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions
Headlines

Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1

2 months ago2 weeks ago

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

2 months ago2 weeks ago

IceCure and Scovas agree for ProSense distribution in Netherlands

2 months ago2 weeks ago

McKesson to buy Precision Medicine Group for $2.25bn

2 months ago2 weeks ago

Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex

2 months ago2 weeks ago

Axoft launches Fleuron WISE polymer for advanced biological imaging

2 months ago2 weeks ago

ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy

2 months ago2 weeks ago

HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial

2 months ago2 weeks ago

PENTAX broadens MAGENTIQ EYE partnership for global AI colonoscopy

2 months ago2 weeks ago

FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911

2 months ago2 weeks ago
  • Home
  • Health & Technology
  • Boston Scientific’s ordering, shipping disrupted in cyberattack
  • Business & Clinical Development
  • Health & Technology
  • Regulatory & Approvals

Boston Scientific’s ordering, shipping disrupted in cyberattack

Health Admin Hub2 months ago2 weeks ago01 mins

The attack affected global operations, and its full scope is still being determined, the medical device maker said in a securities filing.

Source link

Post navigation

Previous: Suki launches AI dictation tool with EHR integration capabilities
Next: No Surprises dispute resolution has generated $22B in extra costs, research finds

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1

Health Admin Hub2 months ago2 weeks ago 0

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

Health Admin Hub2 months ago2 weeks ago 0

IceCure and Scovas agree for ProSense distribution in Netherlands

Health Admin Hub2 months ago2 weeks ago 0

McKesson to buy Precision Medicine Group for $2.25bn

Health Admin Hub2 months ago2 weeks ago 0

Recent Posts

  • Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
  • FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
  • IceCure and Scovas agree for ProSense distribution in Netherlands
  • McKesson to buy Precision Medicine Group for $2.25bn
  • Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex

Pages Lists

  • About US
  • Contact US
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

Categories Lists

  • Business & Clinical Development
  • Health & Technology
  • Regulatory & Approvals
Newsmatic - News WordPress Theme 2026. Powered By BlazeThemes.